Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Legend Biotech Corporation reported $160.21 million in revenue for Q3 2024, a year-over-year increase of 66.9$0.34, compared to -$0.17 a year ago, indicating a decline in profitability [1] - The revenue exceeded the Zacks Consensus Estimate of$144.7 million by 10.72%, while the EPS surprise was +39.29% against the consensus estimate of -$0.56 [1] Revenue Breakdown - Collaboration revenues were$142.83 million, surpassing the average estimate of $132.16 million from seven analysts [3] - License revenues reached$17.10 million, exceeding the average estimate of $13.90 million from five analysts [3] - Other revenues were$0.28 million, falling short of the estimated $2.46 million from two analysts [3] Stock Performance - Over the past month, Legend Biotech's shares have returned -19.4%, contrasting with the Zacks S&P 500 composite's +3.3% change [4] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [4]